Related Experiment Video
Updated: Jun 13, 2025
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
A Prospective European Trial Comparing Laparotomy, Laparoscopy, Robotic-assisted, and Transanal Total Mesorectal
Philippe Rouanet1, Mario Guerrieri2, Pablo Lemercier3
1Department of Oncological Surgery, Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France.
Objective:
To compare total mesorectal excision (TME) techniques combined with sphincter-sparing procedures in high-risk patients (HRPs).
Background:
TME is the standard treatment for rectal cancer, but it can be challenging in HRPs. The available surgical approaches must be compared, especially in HRPs.
Methods:
Prospective, observational, multicenter trial to compare laparotomy (OTME), laparoscopy (LTME), robotic-assisted surgery (RTME), and transanal surgery (TaTME) in HRPs. The composite primary outcome included circumferential radial margin (CRM) ≥1 mm, TME grade II-III, and absence of Clavien-Dindo grade III-IV complications. Three propensity score analyses were performed (LTME vs RTME, RTME vs TaTME, LTME vs TaTME).
Results:
A total of 1078 HRPs (75% of men, median body mass index of 27 kg/m 2 , 50% of tumors in the lower third of the rectum) underwent surgery. The RTME and TaTME groups included patients with more advanced and lower tumors and coloanal anastomosis ( P <0.001). Operative time was longer for RTME surgery ( P <0.001). The conversion rate was similar for minimally invasive procedures (4.5%). The global R0 resection rate was 96% without difference among techniques. The primary outcome rates were 82.4%, 64.3%, 74.7%, and 80.3% for LTME, OTME, RTME, and TaTME, respectively. None achieved the expected success rate (85%), and propensity score analyses found no differences. Operative results were similar between high-volume and low-volume inclusion centers only for RTME.
Conclusions:
The RESET trial yielded high-quality results despite focusing on HRPs. Minimally invasive procedures showed similar sphincter-sparing procedure outcomes, but LTME included patients with more favorable tumors. Oncologic and functional outcomes will be evaluated at 2 years (ClinicalTrials.gov, ID: NCT03574493).
